Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06667141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06667141
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Acrivon Therapeutics
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- ACR-2316 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2024
- Primary completion
- Aug 11, 2026
- Completion
- Dec 11, 2026
- Last update posted
- Mar 22, 2026
2024 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Phoenix | Arizona | 85016 | Recruiting |
| Precision NextGen Oncology & Research Center | Beverly Hills | California | 90212 | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Recruiting |
| Denver Health One | Denver | Colorado | 80218 | Recruiting |
| Florida Cancer Specialist | Sarasota | Florida | 34232 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | Recruiting |
| Montefiore Medical Centre | The Bronx | New York | 10461 | Recruiting |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | Recruiting |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | Recruiting |
| Tennessee Oncology | Franklin | Tennessee | 37067 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77054 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| Next Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06667141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06667141 live on ClinicalTrials.gov.